The cannabidiol and marijuana research expansion act: Promotion of scientific knowledge to prevent a national health crisis.
Level 5 - mechanism / opinion, no new human data
Narrative review and policy commentary with no empirical human data (by design analogy, Level 5).
PubMed 36777382 · doi:10.1016/j.lana.2022.100325
What was done
The authors provided a policy commentary examining U.S. Senate bill S.253 (the Cannabidiol and Marijuana Research Expansion Act, passed by the U.S. Senate in March 2022) and its role in reforming federal regulatory barriers surrounding medical and recreational cannabis research.
What was found
The abstract reports no quantitative empirical data. It describes how federal restrictions hinder cannabis research despite state-level expansion, and outlines how S.253 seeks to facilitate preclinical and clinical research, reinforce legal protections for medical practitioners, and promote physician-patient dialogue about cannabis therapies.
Why it matters
This commentary highlights legislative efforts to lower federal research hurdles, aiming to bridge the gap between widespread public cannabis use and the lack of robust clinical evidence to guide medical practice.
Limits
The paper is a non-systematic legislative commentary that does not contain primary data, patient cohorts, or quantitative analysis. It does not measure the actual regulatory or clinical outcomes resulting from the bill's passage.
Cited by
- supports Around 2020, the United States Congress changed laws regulating cannabis research to make conducting studies simpler.